Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
Cell & Gene Therapy
Biotech
BMS' CAR-T cracks down on lupus, achieving sustained responses
One patient had a grade 3 case of immune effector cell-associated neurotoxicity syndrome, an adverse event associated with CAR-T therapy.
Nick Paul Taylor
Nov 14, 2024 10:00am
Sponsored
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Nov 13, 2024 2:57pm
Bayer drops Huntington's gene therapy
Nov 12, 2024 10:09am
MD Anderson launches cell therapy institute with $80M
Nov 11, 2024 4:20pm
Nkarta continues pivot to lupus by shelving lymphoma program
Nov 8, 2024 8:55am
More News
Carisma's Moderna-powered cell therapy shrinks tumors in mice
Nov 8, 2024 7:30am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Nov 5, 2024 3:08pm
Cellectis drops one of its 3 clinical-stage CAR-Ts
Nov 5, 2024 7:15am
See more stories
